PTEN and prostate carcinoma: To further address the feasibility of PEITC and rapamycin treatment for PTEN-deficient prostate cancer, we employed a mouse model for prostate cancer in which prostate Pten is specifically deleted by Cre recombinase driven by the probasin promoter (Pbsn-Cre4;Ptenf/f mice).